

# OPTIMA HEALTH PLAN

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **Incomplete form will delay authorization process.**

**Drug Requested:** TALTZ® SQ (ixekizumab) (self-administered) (Pharmacy, Non-Preferred)

**DRUG INFORMATION:** Complete all information below or authorization process will be delayed.

Drug Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

### **RECOMMENDED DOSE:**

160mg (two 80mg injections) at Week 0; followed by 80mg at weeks 2, 4, 6, 8, 10, and 12; then 80mg every 4 weeks

**CLINICAL CRITERIA:** **ALL** boxes **MUST** be checked to qualify. Incomplete information will delay authorization process.

Prescriber is a:  Dermatologist  Rheumatologist

**Diagnosis: Moderate to Severe Chronic Plaque Psoriasis**

Patient tried and failed at least **one** of either **Phototherapy** or **Alternative Systemic Therapy** for at least **three (3) months** (check each tried):

- |   |    |   |
|---|----|---|
| <input type="checkbox"/> <b><u>Phototherapy</u></b> | OR | <input type="checkbox"/> <b><u>Alternative Systemic Therapy</u></b> |
| <input type="checkbox"/> <b>UV Light Therapy</b>    |    | <input type="checkbox"/> <b>Oral Alternative Systemic Therapy</b>   |
| <input type="checkbox"/> NB UV-B                    |    | <input type="checkbox"/> acitretin                                  |
| <input type="checkbox"/> PUVA                       |    | <input type="checkbox"/> methotrexate                               |
|   |    | <input type="checkbox"/> cyclosporine                               |

### **AND**

Trial and failure of **one (1)** of the **PREFERRED** Biologics below:

|                                  |                                   |
|----------------------------------|-----------------------------------|
| <input type="checkbox"/> Humira® | <input type="checkbox"/> Stelara® |
| <input type="checkbox"/> Cimzia® | <input type="checkbox"/> Tremfya™ |

### **AND**

Cosentyx®

(continued on next page)

**Diagnosis: Active Psoriatic Arthritis**

Trial and failure of **two (2)** of the **PREFERRED** Biologics below:

|                                  |                                   |
|----------------------------------|-----------------------------------|
| <input type="checkbox"/> Humira® | <input type="checkbox"/> Stelara® |
| <input type="checkbox"/> Cimzia® | <input type="checkbox"/> Simponi® |

**AND**

Both Cosentyx® and Xeljanz®/Xeljanz XR®

**Check Device to be used:**

Auto-Injection or prefilled: 80 mg/mL solution in a single-use

**Medication being provided by a Specialty Pharmacy - PropriumRx**

**\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\***

**\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\***

Patient Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

**DEA OR NPI #:** \_\_\_\_\_

\*Approved by Pharmacy and Therapeutics Committee: 7/21/2016

REVISED/UPDATED: 9/22/2016; 12/11/2016; 8/5/2017; 12/28/2017; 3/14/2018; 6/27/2018; 11/23/2018.